Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

sanofi pasteur europe - influensa virus, inaktiverat, med split) av följande stammar:a/california/7/2009 (h1n1)pdm09 - liknande stam (a/california/7/2009, nymc x-179a)a/hong kong/4801/2014 (h3n2) - liknande stam (a/hong kong/4801/2014, nymc x-263b)b/brisbane/60/2008 - som stam (b/brisbane/60/2008, wild-type) - influenza, human; immunization - vacciner - profylax av influensa hos individer 60 år och äldre, särskilt hos dem som löper ökad risk för associerade komplikationer. användning av intanza bör baseras på officiella rekommendationer.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - grisar - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

Ευρωπαϊκή Ένωση - Σουηδικά - EMA (European Medicines Agency)

zoetis belgium sa - synthetic peptide analogue of gnrf conjugated to diptheria toxoid - immunologiska medel för suidae - male pigs (from 8 weeks of age); female pigs (from 14 weeks of age) - male pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of testicular function. for use as an alternative to physical castration for the reduction of boar taint caused by the key boar taint compound androstenone, in entire male pigs following the onset of puberty. en annan viktig bidragsgivare till vildsvin, skatole, kan också minskas som en indirekt effekt. aggressiva och sexuella (montering) beteenden minskar också. female pigs:induction of antibodies against gnrf to produce a temporary immunological suppression of ovarian function (suppression of oestrus) in order to reduce the incidence of unwanted pregnancies in gilts intended for slaughter, and to reduce the associated sexual behaviour (standing oestrus).

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

hospira uk limited - vinorelbintartrat - koncentrat till infusionsvätska, lösning - 10 mg/ml - vinorelbintartrat 13,85 mg aktiv substans - vinorelbin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

ebewe pharma ges.m.b.h.nfg.kg - vinorelbintartrat - koncentrat till infusionsvätska, lösning - 10 mg/ml - vinorelbintartrat 13,85 mg aktiv substans - vinorelbin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

ethypharm sa - adrenalintartrat - injektionsvätska, lösning - 0,1 mg/ml - adrenalintartrat 0,18 mg aktiv substans; natriummetabisulfit hjälpämne - adrenalin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

mylan ab - adrenalintartrat - injektionsvätska, lösning - 1 mg/ml - natriummetabisulfit hjälpämne; adrenalintartrat 1,82 mg aktiv substans - adrenalin

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

intervet international b.v. - butorfanoltartrat - injektionsvätska, lösning - 10 mg/ml - butorfanoltartrat 14,6 mg aktiv substans - butorfanol - hund, häst, katt

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

animedica gmbh - butorfanoltartrat - injektionsvätska, lösning - 10 mg/ml - butorfanoltartrat 14,7 mg aktiv substans - butorfanol - häst

Σουηδία - Σουηδικά - Läkemedelsverket (Medical Products Agency)

vetviva richter gmbh - butorfanoltartrat - injektionsvätska, lösning - 10 mg/ml - butorfanoltartrat 14,58 mg aktiv substans - butorfanol - hund, häst, katt